Abstract 27P
Background
Up to 36% of patients with localized colon cancer (LCC) do not clear circulating tumor DNA after adjuvant chemotherapy (ACT) and experience a recurrence. Identifying recurrence risk signatures and selecting patients for more personalized adjuvant therapies relies on comprehending cellular resistance mechanisms and the host tissue microenvironment. Our project's goal is to analyze the proteomic profile of primary tumors (PTs) with a high risk of relapse and organ-specific metastatic lesions to enhance personalized therapeutic strategies.
Methods
At the Hospital Clínico Universitario of Valencia, Spain, we conducted a proteomic analysis using SWATH mass spectrometry on 80 tissue samples from patients with LCC. Of these, 28 PTs samples from non-relapsed patients and 52 samples of 25 relapsed patients with PTs and paired metastases (METs) were analyzed. Differential expression (DE) analysis was performed using the R package Limma and functional enrichment analysis was done by GO, with a significance threshold set at FDR<0.05.
Results
SWATH analysis revealed 308 DE proteins between PTs and METs, with 12 proteins being overexpressed in METs and 296 in PTs. Interestingly, distinctive proteomic profiles were observed among different metastatic sites, particularly in liver lesions. GO analysis of the overexpressed MET proteins indicated enrichment in nucleic acid binding and structural molecule activity. The proteins overexpressed in PTs showed enrichment in catalytic and oxidoreductase activity, as well as molecule binding, among the top 10 pathways. Additionally, when comparing PTs from relapsed and non-relapsed patients, 206 DE proteins were identified. A Cox survival analysis revealing changes in protein levels associated with worse disease-free survival, including IWS1 and DPYSL4.
Conclusions
We discovered a specific proteomic signature for metastases, particularly in liver lesions, highlighting the significance of organ-specificity in metastatic development. Moreover, we identified novel proteins as potential biomarkers for poor prognosis in primary tissue, improving patient risk stratification.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Instituto de Salud Carlos III.
Disclosure
V. Gambardella: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Institutional, Other, Research: Research Funding: Bayer, Boehringer Ingelheim; Roche; Financial Interests, Institutional, Other, Institutional: Institutional Funding: Genentech, Merck, Roche, Bayer, Lilly, Novartis, Takeda, AstraZeneca, BM. A. Cervantes: Financial Interests, Institutional, Advisory Board: Merck-Serono, Amgen, Roche, Transgene, AnHeart Therapeutics, AbbVie, GSK; Financial Interests, Institutional, Invited Speaker: Amgen, Roche, Merck Serono, Foundation Medicine; Financial Interests, Personal, Other, Associate Editor: Annals of Oncology, ESMO Open; Financial Interests, Personal, Other, Editor in Chief: Cancer Treatment Reviews; Financial Interests, Institutional, Research Grant, Principal Investigator: Actuate Therapeutic, Amgen, Astellas Pharma, Beigene, Bayer, AstraZeneca, BMS, Amcure, FibroGen, Lilly, Genentech, MedImmune, Merck Serono, Novartis, Natera, MSD, Servier, Sierra Oncology, Adaptimmune, Takeda, Affimed, Roche, Seamless, Gilead, Janssen, F. STAR Therapeutics, Ribon Therapeutics; Non-Financial Interests, Personal, Other, Scientific Director: INCLIVA Biomedical Research Institute. N. Tarazona Llavero: Financial Interests, Personal, Advisory Board: Merck, Guardant Health; Financial Interests, Personal, Invited Speaker: Merck, Pfizer, Servier, Amgen; Financial Interests, Institutional, Funding: Natera Inc.; Non-Financial Interests, Personal, Member: SEOM Committee. All other authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract